ProCE Banner Activity

New Perspectives on the Treatment of Multiple Myeloma In The Relapse Setting: Case Discussion and Common Clinical Scenarios

Slideset Download
Download these expert-selected slides on treatments for early and later-stage relapsed/refractory multiple myeloma.

Released: October 06, 2022

Expiration: October 05, 2023

Share

Faculty

Sagar Lonial

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Thomas G. Martin

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Bristol Myers Squibb

Janssen administered by Scientific Affairs

Karyopharm Therapeutics

Faculty Disclosure

Primary Author

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Sagar Lonial, MD: consultant/advisor/speaker: AbbVie, Amgen, Bristol-Myers Squibb, Celgene, GlaxoSmithKline, Janssen, Novartis, Takeda; researcher: Bristol-Myers Squibb, Janssen, Novartis, Takeda; board member with stock: TG Therapeutics.

Thomas G. Martin, MD

Associate Clinical Professor of Medicine
Associate Director
, Myeloma Institute
University of California, San Francisco Medical Center
San Francisco, California

Thomas G. Martin, MD: consultant: GlaxoSmithKline; researcher: Amgen, Janssen, Sanofi, Seattle Genetics.